Shares of Structure Therapeutics Inc. (NASDAQ: GPCR) are soaring 5.05% in pre-market trading on Monday, following the company's announcement of positive results from a mid-stage study of its experimental oral obesity drug. The biotechnology firm, which specializes in G protein-coupled receptor (GPCR) drug discovery, is gaining investor attention in the increasingly competitive weight-loss drug market.

According to the company's recent report, Structure Therapeutics' oral obesity drug candidate demonstrated encouraging efficacy in a mid-stage clinical trial. The experimental treatment helped participants achieve an average weight reduction of 6.2% over a 12-week period. This outcome positions Structure Therapeutics as a potential contender in the rapidly growing market for obesity treatments, which is currently dominated by injectable drugs from pharmaceutical giants like Novo Nordisk and Eli Lilly.

The positive results from Structure Therapeutics come at a time when the weight-loss drug market is heating up, with forecasts projecting it to reach $150 billion by the early 2030s. As one of the few companies developing an oral medication for obesity, Structure Therapeutics' progress is being closely watched by investors and industry analysts. The pre-market stock surge reflects growing optimism about the company's potential to capture a share of this lucrative market with a more convenient oral formulation.